Faisal Fakih
Winter Park, FLNPI 1386635480
Payments from drug & device makers
Across 2,848 payments — averaging $6358.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$10M
- Pfizer$2.6M
- Astrazeneca UK Limited$1.2M
- AstraZeneca$979K
- Alkermes, Inc.$342K
- Takeda Pharmaceuticals U.S.A., Inc.$331K
- plus $2.6M from 20 others
Across 31 payments — averaging $131.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Eli Lilly$463
What the payments were for
- Consulting fees$2,08028%
- Travel & lodging$4,15055%
- Food & beverage$1,28717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 765 | $9,980,137 |
| Pfizer | 178 | $2,604,926 |
| Astrazeneca UK Limited | 13 | $1,232,115 |
| AstraZeneca | 61 | $978,621 |
| Alkermes, Inc. | 267 | $341,969 |
| Takeda Pharmaceuticals U.S.A., Inc. | 71 | $331,178 |
| Novartis | 30 | $315,826 |
| Eisai Inc. | 12 | $275,237 |
| Alnylam Pharmaceuticals Inc. | 1,041 | $264,867 |
| Genentech, Inc. | 82 | $263,082 |
| Teva Pharmaceuticals USA, Inc. | 20 | $220,789 |
| Merck | 72 | $219,753 |
| Astrazeneca AB | 6 | $210,187 |
| Chugai Pharmaceutical Co., Ltd. | 28 | $200,116 |
| Roche Products Limited | 20 | $142,294 |
| Sanofi US Services Inc. | 28 | $101,698 |
| AbbVie | 26 | $98,564 |
| Biogen | 3 | $60,568 |
| Travere Therapeutics, Inc. | 48 | $56,319 |
| E.r. Squibb & Sons, L.L.C. | 4 | $47,648 |
| Avanir Pharmaceuticals, Inc. | 7 | $45,108 |
| Chiesi USA, Inc. | 7 | $40,050 |
| Incyte Corporation | 7 | $29,433 |
| Boehringer Ingelheim Canada Ltd.ltee | 48 | $26,447 |
| Vertex | 2 | $18,224 |
| Boehringer Ingelheim | 2 | $2,536 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$1,226
- MK-7264$1,007
- QBW251$551
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.